Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14098539 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL5093549 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL20241819 | 0.94 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL12873750 | 0.85 | GRM5 (0.39) | CHRM2CHRM1CHRM3KCNK3KCNK9 | |
| SCHEMBL24208627 | 0.82 | CHRM2 (0.53) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL30777200 | 0.82 | CHRM2 (0.53) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL3132747 | 0.81 | CHRM1 (0.38) | CHRM1GPR119 | |
| SCHEMBL17517301 | 0.81 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL17861592 | 0.80 | CHRM2 (0.62) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2708300 | 0.80 | CHRM2 (0.62) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720041-A2 | N-(1H-INDOL-2-YL)METHYL)-4-ETHYNYL-PICOLINAMIDE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Allorion Therapeutics Inc (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025093870-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-08 | — | — | WO | disclosed |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc | 2025-01-23 | — | — | US | disclosed |
| WO-2024240241-A2 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc (US) | 2024-11-28 | — | — | WO | disclosed |
| US-11072602-B2 | Antidiabetic heterocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2021-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072602-B2 | Antidiabetic heterocyclic compounds | GPR119, GLP1R, GPR65 | CHRM2 816/4885CHRM1 1214/4885CHRM3 760/4885 |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | CHRM2 4561/4885CHRM1 4533/4885CHRM3 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.